1.88
price up icon3.30%   0.06
after-market After Hours: 1.88
loading
Akebia Therapeutics Inc stock is traded at $1.88, with a volume of 2.00M. It is up +3.30% in the last 24 hours and up +14.63% over the past month. Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
See More
Previous Close:
$1.82
Open:
$1.84
24h Volume:
2.00M
Relative Volume:
1.12
Market Cap:
$410.18M
Revenue:
$194.75M
Net Income/Loss:
$-51.26M
P/E Ratio:
-3.6154
EPS:
-0.52
Net Cash Flow:
$-23.38M
1W Performance:
+5.03%
1M Performance:
+14.63%
6M Performance:
+70.91%
1Y Performance:
+89.90%
1-Day Range:
Value
$1.805
$1.8995
1-Week Range:
Value
$1.75
$1.8995
52-Week Range:
Value
$0.80
$2.48

Akebia Therapeutics Inc Stock (AKBA) Company Profile

Name
Name
Akebia Therapeutics Inc
Name
Phone
617-871-2098
Name
Address
245 FIRST STREET, CAMBRIDGE, MA
Name
Employee
167
Name
Twitter
@akebiatx
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
AKBA's Discussions on Twitter

Compare AKBA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
AKBA 1.88 410.18M 194.75M -51.26M -23.38M -0.52
ZTS 176.96 79.84B 9.15B 2.43B 2.31B 4.92
HLN 9.65 43.63B 14.26B 1.55B 0 0.3327
TAK 13.38 42.42B 30.27B 1.93B 3.45B 0.444
TEVA 17.12 19.40B 16.77B -959.00M 1.37B -2.00
VTRS 13.37 15.96B 15.05B -883.30M 1.89B 1.53

Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-31-22 Downgrade H.C. Wainwright Buy → Neutral
Mar-31-22 Downgrade Mizuho Buy → Neutral
Mar-31-22 Downgrade Needham Buy → Hold
Mar-31-22 Downgrade Piper Sandler Overweight → Neutral
Mar-08-21 Initiated Cantor Fitzgerald Overweight
Jan-29-21 Downgrade JP Morgan Neutral → Underweight
Nov-14-19 Reiterated Needham Buy
Aug-06-19 Reiterated H.C. Wainwright Buy
Jul-11-19 Reiterated H.C. Wainwright Buy
May-02-19 Initiated JP Morgan Overweight
Mar-20-19 Initiated Citigroup Neutral
Sep-07-18 Resumed Morgan Stanley Equal-Weight
Aug-10-18 Reiterated Needham Buy
Jun-06-18 Reiterated H.C. Wainwright Buy
Dec-19-17 Initiated Piper Jaffray Overweight
Dec-07-17 Initiated BTIG Research Buy
Sep-15-17 Initiated RBC Capital Mkts Sector Perform
Jul-10-17 Reiterated H.C. Wainwright Buy
Apr-27-17 Reiterated H.C. Wainwright Buy
Apr-27-17 Reiterated Needham Buy
Dec-27-16 Reiterated H.C. Wainwright Buy
Dec-20-16 Reiterated JMP Securities Mkt Outperform
Nov-15-16 Initiated Aegis Capital Buy
Sep-29-16 Initiated Brean Capital Buy
Mar-16-16 Reiterated Needham Buy
Jan-21-16 Initiated Credit Suisse Neutral
View All

Akebia Therapeutics Inc Stock (AKBA) Latest News

pulisher
Nov 23, 2024

Akebia Therapeutics to Present at the Jefferies London Healthcare Conference - GuruFocus.com

Nov 23, 2024
pulisher
Nov 23, 2024

Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - GuruFocus.com

Nov 23, 2024
pulisher
Nov 23, 2024

Vadadustat Alternative Dosing Study Results Published in the Ame - GuruFocus.com

Nov 23, 2024
pulisher
Nov 22, 2024

Akebia Therapeutics to Report Third Quarter 2024 Financial Resul - GuruFocus.com

Nov 22, 2024
pulisher
Nov 22, 2024

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listi - GuruFocus.com

Nov 22, 2024
pulisher
Nov 22, 2024

Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply C - GuruFocus.com

Nov 22, 2024
pulisher
Nov 22, 2024

Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024 - GuruFocus.com

Nov 22, 2024
pulisher
Nov 20, 2024

Q3 2024 Earnings: Hold Akebia Therapeutics (NASDAQ:AKBA) - Seeking Alpha

Nov 20, 2024
pulisher
Nov 14, 2024

Akebia's FDA-Approved Vafseo Shows Promise in Key Dialysis Trial Results | AKBA Stock News - StockTitan

Nov 14, 2024
pulisher
Nov 13, 2024

Akebia Therapeutics (NASDAQ:AKBA) Stock Rating Lowered by StockNews.com - Defense World

Nov 13, 2024
pulisher
Nov 09, 2024

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 09, 2024
pulisher
Nov 09, 2024

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$5.50 - Yahoo Finance

Nov 09, 2024
pulisher
Nov 08, 2024

Earnings call: Akebia reports Q3 results, gears up for Vafseo launch - Investing.com Australia

Nov 08, 2024
pulisher
Nov 08, 2024

Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Price Is Right But Growth Is Lacking After Shares Rocket 41% - Simply Wall St

Nov 08, 2024
pulisher
Nov 08, 2024

Akebia Therapeutics Inc (AKBA) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ... By GuruFocus - Investing.com Canada

Nov 08, 2024
pulisher
Nov 08, 2024

Akebia Therapeutics Inc (AKBA) Q3 2024 Earnings Call Highlights: - GuruFocus.com

Nov 08, 2024
pulisher
Nov 08, 2024

Akebia Therapeutics Inc (AKBA) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ... - Yahoo Finance

Nov 08, 2024
pulisher
Nov 08, 2024

Akebia Therapeutics: Q3 Earnings Snapshot - CT Insider

Nov 08, 2024
pulisher
Nov 08, 2024

Akebia Therapeutics Prepares for Vafseo Launch - TipRanks

Nov 08, 2024
pulisher
Nov 07, 2024

Akebia Therapeutics Inc. (AKBA) Quarterly 10-Q Report - Quartzy

Nov 07, 2024
pulisher
Nov 07, 2024

Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance

Nov 07, 2024
pulisher
Nov 07, 2024

SEC Form 10-Q filed by Akebia Therapeutics Inc. - Quantisnow

Nov 07, 2024
pulisher
Nov 06, 2024

Here's Why You Should Consider Buying Akebia (AKBA) Stock - MSN

Nov 06, 2024
pulisher
Nov 04, 2024

Akebia Therapeutics to present at upcoming investor conferences - MSN

Nov 04, 2024
pulisher
Nov 02, 2024

Akebia Therapeutics (AKBA) Scheduled to Post Earnings on Thursday - MarketBeat

Nov 02, 2024
pulisher
Nov 01, 2024

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Lelezard

Nov 01, 2024
pulisher
Nov 01, 2024

Akebia Therapeutics Signs Commercial Supply Contract with Leadin - GuruFocus.com

Nov 01, 2024
pulisher
Nov 01, 2024

Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights - citybiz

Nov 01, 2024
pulisher
Oct 31, 2024

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Short Interest Down 6.0% in October - Defense World

Oct 31, 2024
pulisher
Oct 31, 2024

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Short Interest Update - MarketBeat

Oct 31, 2024
pulisher
Oct 29, 2024

EasyA x Polkadot Hackathon startup lands a spot at Y Combinator - Investing.com

Oct 29, 2024
pulisher
Oct 25, 2024

Akebia Therapeutics (NASDAQ:AKBA) Stock Rating Reaffirmed by HC Wainwright - Defense World

Oct 25, 2024
pulisher
Oct 23, 2024

Akebia stock climbs 8% on dialysis provider supply agreement - MSN

Oct 23, 2024
pulisher
Oct 23, 2024

High Growth Tech Stocks to Watch in October 2024 - Simply Wall St

Oct 23, 2024
pulisher
Oct 23, 2024

Akebia Therapeutics (NASDAQ:AKBA) shareholder returns have been respectable, earning 91% in 1 year - Simply Wall St

Oct 23, 2024
pulisher
Oct 22, 2024

Akebia Therapeutics secures dialysis drug contract By Investing.com - Investing.com Australia

Oct 22, 2024
pulisher
Oct 22, 2024

Akebia Therapeutics secures dialysis drug contract - Investing.com

Oct 22, 2024
pulisher
Oct 22, 2024

Akebia Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow

Oct 22, 2024
pulisher
Oct 22, 2024

Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis - Yahoo Finance

Oct 22, 2024
pulisher
Oct 17, 2024

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class ActionAKBA - AsiaOne

Oct 17, 2024
pulisher
Oct 16, 2024

Akebia Therapeutics extends supply agreement with STA Pharmaceutical - Investing.com

Oct 16, 2024
pulisher
Oct 16, 2024

Akebia Therapeutics extends supply agreement with STA Pharmaceutical By Investing.com - Investing.com UK

Oct 16, 2024
pulisher
Oct 16, 2024

Akebia Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement - Quantisnow

Oct 16, 2024

Akebia Therapeutics Inc Stock (AKBA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$90.52
price up icon 3.66%
$13.36
price down icon 0.30%
$85.69
price up icon 0.28%
$60.98
price up icon 2.21%
$125.65
price up icon 0.52%
$13.37
price up icon 0.91%
Cap:     |  Volume (24h):